AFTER THE OPEN
- As at 10:55am, here’s how the stocks that had significant announcements this morning or after the close yesterday are performing.
- The ASX:REA result looked strong but their outlook looked weak / conservative.
- ASX:PTM and ASX:AQZ both reported after the close yesterday. This is usually not a great sign and clearly today the market is confirming that. Silly.
- Yesterday, Cettire (ASX:CTT) had a great day and is continuing to rise today. It is in the model portfolio. I will have a closer look at them for members today.
BEFORE THE MARKET OPEN
Telix Pharmaceuticals (ASX:TLX)
- Telix Pharmaceuticals (ASX:TLX) announces a new acquisition. Late stage radiopharmaceutical for primary and metastatic bone cancer. Complimentary to say the least. If you don’t know why I say that, do some reading on Telix Pharmaceuticals (ASX:TLX) – it’s well worth it – for humanity let alone as a potential investment.
- It’s been a while since the gold price did anything of note.
- Strong night in the US and some good results after the close for ARM and Disney. Yet our futures have had a muted response up just 3 points. Looking at commodities copper and iron ore dropped so I suspect that is the reason. Hopefully the positivity from the US will flow through to other parts of our market today.
Playside (ASX:PLY)
https://www.playsidestudios.com/
- Good news and bad news for Playside (ASX:PLY). Good news for them as they no longer need to lodge quarterly reports which means business is good (cash-flow positive for 4 quarters in a row) but bad for me as I really like the more regularity of quarterly cash-flow reports.
Cochlear (ASX:COH)
https://www.cochlear.com/au/en/home
- Profit upgrade for Cochlear (ASX:COH). My favourite kind of announcement.
- They have been going good though so you would think the market was to some degree already expecting good things. Nevertheless, it should be a good day for shareholders.
Disclaimer: This information is provided purely for educational purposes. It takes no account of an individual’s personal financial circumstances and hence can in no way constitute financial advice. The above data may be subject to errors or inconsistencies for which the author takes no liability. It is imperative that all investors do their own research or if they need advice, seek it from a qualified financial adviser.